Pharmaceutical

Esperion snags US label expansion for cardiovascular disease drugs

Esperion Therapeutics’ Nexletol and Nexlizet are now available for patients with cardiovascular risk in the US.

Mar 26, 2024 - 00:00
Esperion snags US label expansion for cardiovascular disease drugs
Esperion Therapeutics’ Nexletol and Nexlizet are now available for patients with cardiovascular risk in the US.
Read the original article

Tags:

Previous Article

CRISPR-based assay could revolutionise diagnosis of NTM infections

Next Article

AriBio licenses Alzheimer’s pill in China for up to $770m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Lilly’s obesity pill cuts 15% of weight at highest dose in mid-stage trial

STAT+: Lilly’s obesity pill cuts 15% of weight at highe...

Jun 24, 2023

STAT+: European regulator will review study data from contract research organization due to ‘serious concerns’

STAT+: European regulator will review study data from c...

Jul 22, 2023

Carmell to merge with regenerative medicine company Axolotl

Carmell to merge with regenerative medicine company Axo...

Jul 29, 2023